Navigation Links
U.S. Bests Canada, Europe in Drug Approvals
Date:5/16/2012

WEDNESDAY, May 16 (HealthDay News) -- New drugs are approved faster in the United States than in Europe and Canada, new research shows.

The findings counter a common belief that the drug-approval process by the U.S. Food and Drug Administration is especially slow, according to Yale University School of Medicine researchers.

The study authors reviewed drug-approval decisions made between 2001 and 2010 by the FDA, Health Canada (the Canadian drug regulator), and the European Medicines Agency (EMA). The latter agencies were chosen for comparison with the FDA because they face similar pressures to approve new drugs quickly while ensuring patient safety, the researchers said.

"Among the subsample of drugs approved for all three regulators, the FDA's reviews were over three months faster than those of the EMA or Health Canada," study leader Nicholas Downing, a second-year medical student, said in a university news release.

"The total review time at the FDA was faster than EMA, despite the FDA's far higher proportion of applications requiring multiple regulatory reviews," he added.

The study also revealed that most new drug therapies were first approved for use in the United States.

"Examining novel drugs approved in multiple markets, we found that 64 percent of medicines approved in both the U.S. and in Europe were approved for U.S. patients first, and 86 percent of medicines approved in both the U.S. and Canada were also approved first in the U.S.," Downing said.

The study was published online May 16 in the New England Journal of Medicine.

More information

The FDA explains how it approves drugs.

-- Robert Preidt

SOURCE: Yale University, news release, May 16, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. ‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail!
2. Brown Rice Bests White for Diabetes Prevention
3. TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List
4. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
5. Grays Anatomy for Students, worlds bestselling anatomy textbooks, now available on iPad
6. Experimental Psoriasis Drug Bests Older Treatment
7. New procedure bests standard of care for fixing damaged cartilage
8. Report: For every 1 homeless person in Canada, another 23 live in inadequate housing
9. End-of-Life Care Differs Between U.S., Canada, Study Finds
10. New High Purity Immunoglobulin Enters Phase III in Europe and the US
11. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U.S. Bests Canada, Europe in Drug Approvals
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Top ... Smiling Patriot program today with a new Indiegogo campaign . Individuals ... to homeless veterans in the Los Angeles area, either as a participating patient or ...
(Date:2/22/2017)... New York (PRWEB) , ... February 22, 2017 ... ... floor entrance and lobby of a new healthcare contact center in Georgia, PENETRON ... , One of the nation’s largest healthcare systems recently invested $51 million to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... The top three players dominating ... Koninklijke Philips N.V., and Schiller. Collectively, these companies held ... in 2015. Strong product portfolio and a monumental geographical ... aiding these players remain leaders in the fragmented competitive ... the global market are likely to focus on mergers ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
(Date:2/23/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced its year end 2016 ... In January 2017, OncoGenex, and Achieve Life Science, Inc., ... have entered into a definitive merger agreement under which ... completion of the proposed merger, Achieve,s stockholders are expected ...
Breaking Medicine Technology: